The Office of the Drugs Control General of India (DCGI) has given approval to Sun Pharma to market Escitalopram, the Indian version of antidepressant drug Lexapro. The branded Escitalopram is manufactured by US based Forest Laboratories.
Escitalopram, which is a form of Citalopram again a product (Celexa), also owned by Forest Laboratories. Celexa is currently indicated for the treatment of depression in adults aged 18 and older. Prescribed for more than six million U.S. patients, Celexa is the fastest growing antidepressant in the U.S. Escitalopram is a single isomer derived from Celexa.
Along with Sun's Escitalopram, the DCGI has also given approval for four more new drugs. These drugs are Cilastozaole, an intermittent clodication from Glenmark, Cesprozile Tab 250/500 mg Syrup 125mg/ml an antibiotic manufactured by Ranbaxy/Orchid and Domeperidone SR Tab 300 mg of TPL and Rofecoxib Injection of Themis.